FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888247845> ?p ?o ?g. }

• W2888247845 abstract "NeoRes I is a randomized phase II trial comparing neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy in the treatment of resectable cancer of the esophagus or gastroesophageal junction. Patients with biopsy-proven adenocarcinoma or squamous cell carcinoma, T1N1 or T2-3N0-1 and M0-M1a (AJCC 6th ed.), were randomized to receive three 3-weekly cycles of cisplatin 100 mg/m2 day 1 and fluorouracil 750 mg/m2/24 hours, days 1–5 with or without the addition of concurrent radiotherapy 40 Gy, 2 Gy/fraction, 5 days a week, followed by esophageal resection with two-field lymphadenectomy. Primary endpoint was complete histopathological response rate in the primary tumor. Survival and recurrence patterns were evaluated as secondary endpoints. Between 2006 and 2013, 181 patients were enrolled in Sweden and Norway. All three chemotherapy cycles were delivered to 73% of the patients allocated to chemoradiotherapy and to 86% of the patients allocated to chemotherapy. 87% of those allocated to chemoradiotherapy received full dose radiotherapy. 87% in the chemoradiotherapy group and 86% in the chemotherapy group underwent tumor resection. Initial results showed that patients allocated to chemoradiotherapy more often responded with complete histopathological response in the primary tumor (28% vs. 9%). Treatment-related complications were similar between the groups although postoperative complications were more severe in the chemoradiotherapy group. This article reports the long-term results. Five-year progression-free survival was 38.9% (95% CI 28.9%–48.8%) in the chemoradiotherapy group versus 33.0% (95% CI 23.6%–42.7%) in the chemotherapy group, P = 0.82. Five-year overall survival was 42.2% (95% CI 31.9%–52.1%) versus 39.6% (95% CI 29.5%–49.4%), P = 0.60. There were no differences in recurrence patterns between the treatment groups. This is to our knowledge that the largest completed randomized trial comparing neoadjuvant chemotherapy with neoadjuvant chemoradiotherapy followed by esophageal resection in patients with cancer in the esophagus or gastroesophageal junction. Despite a higher tumor tissue response in those who received neoadjuvant chemoradiotherapy, no survival advantages were seen. Consequently, the results do not support unselected addition of radiotherapy to neoadjuvant chemotherapy as a standard of care in patients with resectable esophageal cancer." @default.
• W2888247845 created "2018-08-31" @default.
• W2888247845 creator A5005280125 @default.
• W2888247845 creator A5008218901 @default.
• W2888247845 creator A5014746376 @default.
• W2888247845 creator A5025268748 @default.
• W2888247845 creator A5038683663 @default.
• W2888247845 creator A5050796430 @default.
• W2888247845 creator A5065850011 @default.
• W2888247845 creator A5066912056 @default.
• W2888247845 creator A5069262726 @default.
• W2888247845 creator A5078265692 @default.
• W2888247845 creator A5081448534 @default.
• W2888247845 creator A5081863789 @default.
• W2888247845 date "2018-08-22" @default.
• W2888247845 modified "2023-10-11" @default.
• W2888247845 title "Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial" @default.
• W2888247845 cites W1542225879 @default.
• W2888247845 cites W1865426939 @default.
• W2888247845 cites W1922694287 @default.
• W2888247845 cites W1978983264 @default.
• W2888247845 cites W1981596218 @default.
• W2888247845 cites W1991507882 @default.
• W2888247845 cites W2054305985 @default.
• W2888247845 cites W2060259050 @default.
• W2888247845 cites W2064875052 @default.
• W2888247845 cites W2089609493 @default.
• W2888247845 cites W2111674123 @default.
• W2888247845 cites W2133028942 @default.
• W2888247845 cites W2141666552 @default.
• W2888247845 cites W2154444715 @default.
• W2888247845 cites W2291509448 @default.
• W2888247845 cites W2726987475 @default.
• W2888247845 cites W2733330634 @default.
• W2888247845 doi "https://doi.org/10.1093/dote/doy078" @default.
• W2888247845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30137281" @default.
• W2888247845 hasPublicationYear "2018" @default.
• W2888247845 type Work @default.
• W2888247845 sameAs 2888247845 @default.
• W2888247845 citedByCount "82" @default.
• W2888247845 countsByYear W28882478452019 @default.
• W2888247845 countsByYear W28882478452020 @default.
• W2888247845 countsByYear W28882478452021 @default.
• W2888247845 countsByYear W28882478452022 @default.
• W2888247845 countsByYear W28882478452023 @default.
• W2888247845 crossrefType "journal-article" @default.
• W2888247845 hasAuthorship W2888247845A5005280125 @default.
• W2888247845 hasAuthorship W2888247845A5008218901 @default.
• W2888247845 hasAuthorship W2888247845A5014746376 @default.
• W2888247845 hasAuthorship W2888247845A5025268748 @default.
• W2888247845 hasAuthorship W2888247845A5038683663 @default.
• W2888247845 hasAuthorship W2888247845A5050796430 @default.
• W2888247845 hasAuthorship W2888247845A5065850011 @default.
• W2888247845 hasAuthorship W2888247845A5066912056 @default.
• W2888247845 hasAuthorship W2888247845A5069262726 @default.
• W2888247845 hasAuthorship W2888247845A5078265692 @default.
• W2888247845 hasAuthorship W2888247845A5081448534 @default.
• W2888247845 hasAuthorship W2888247845A5081863789 @default.
• W2888247845 hasBestOaLocation W28882478451 @default.
• W2888247845 hasConcept C121608353 @default.
• W2888247845 hasConcept C126322002 @default.
• W2888247845 hasConcept C141071460 @default.
• W2888247845 hasConcept C143998085 @default.
• W2888247845 hasConcept C168563851 @default.
• W2888247845 hasConcept C203092338 @default.
• W2888247845 hasConcept C2776694085 @default.
• W2888247845 hasConcept C2777297899 @default.
• W2888247845 hasConcept C2777819096 @default.
• W2888247845 hasConcept C2778292576 @default.
• W2888247845 hasConcept C2778424827 @default.
• W2888247845 hasConcept C2779742542 @default.
• W2888247845 hasConcept C2780456651 @default.
• W2888247845 hasConcept C2780824555 @default.
• W2888247845 hasConcept C2781182431 @default.
• W2888247845 hasConcept C509974204 @default.
• W2888247845 hasConcept C530470458 @default.
• W2888247845 hasConcept C71924100 @default.
• W2888247845 hasConceptScore W2888247845C121608353 @default.
• W2888247845 hasConceptScore W2888247845C126322002 @default.
• W2888247845 hasConceptScore W2888247845C141071460 @default.
• W2888247845 hasConceptScore W2888247845C143998085 @default.
• W2888247845 hasConceptScore W2888247845C168563851 @default.
• W2888247845 hasConceptScore W2888247845C203092338 @default.
• W2888247845 hasConceptScore W2888247845C2776694085 @default.
• W2888247845 hasConceptScore W2888247845C2777297899 @default.
• W2888247845 hasConceptScore W2888247845C2777819096 @default.
• W2888247845 hasConceptScore W2888247845C2778292576 @default.
• W2888247845 hasConceptScore W2888247845C2778424827 @default.
• W2888247845 hasConceptScore W2888247845C2779742542 @default.
• W2888247845 hasConceptScore W2888247845C2780456651 @default.
• W2888247845 hasConceptScore W2888247845C2780824555 @default.
• W2888247845 hasConceptScore W2888247845C2781182431 @default.
• W2888247845 hasConceptScore W2888247845C509974204 @default.
• W2888247845 hasConceptScore W2888247845C530470458 @default.
• W2888247845 hasConceptScore W2888247845C71924100 @default.
• W2888247845 hasFunder F4320321491 @default.
• W2888247845 hasFunder F4320322570 @default.
• W2888247845 hasFunder F4320324251 @default.
• W2888247845 hasFunder F4320324618 @default.
• W2888247845 hasIssue "2" @default.

• next